These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 6912276)
21. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Fearon DT Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688 [TBL] [Abstract][Full Text] [Related]
22. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase. DiScipio RG Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218 [TBL] [Abstract][Full Text] [Related]
23. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. Fearon DT J Exp Med; 1980 Jul; 152(1):20-30. PubMed ID: 6967510 [TBL] [Abstract][Full Text] [Related]
24. Monocyte/macrophage interactions with base and linear- and star-like PEG-modified PEG-poly(acrylic acid) co-polymers. Wagner VE; Bryers JD J Biomed Mater Res A; 2003 Jul; 66(1):62-78. PubMed ID: 12833432 [TBL] [Abstract][Full Text] [Related]
25. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384 [TBL] [Abstract][Full Text] [Related]
26. Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. Ross GD; Lambris JD J Exp Med; 1982 Jan; 155(1):96-110. PubMed ID: 6915077 [TBL] [Abstract][Full Text] [Related]
27. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions. Fishelson Z; Müller-Eberhard HJ Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181 [TBL] [Abstract][Full Text] [Related]
28. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. Moore FD; Austen KF; Fearon DT J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957 [TBL] [Abstract][Full Text] [Related]
29. In vivo modulation of rat complement activities by infusion of anti-H antibodies. Veerhuis R; van Es LA; Daha MR Immunobiology; 1985 Sep; 170(3):133-45. PubMed ID: 2932382 [TBL] [Abstract][Full Text] [Related]
30. The role of complement in the function of the monocyte - macrophage system. Schorlemmer HU Haematol Blood Transfus; 1981; 27():59-71. PubMed ID: 6976918 [TBL] [Abstract][Full Text] [Related]
31. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Pangburn MK; Müller-Eberhard HJ Biochem J; 1986 May; 235(3):723-30. PubMed ID: 3638964 [TBL] [Abstract][Full Text] [Related]
32. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor. Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408 [TBL] [Abstract][Full Text] [Related]
33. The functional inhibition of activated C1 inhibitor in normal human serum causes spontaneous consumption of the complement components C2, C3, C4, and factor B. Gronski P; Bodenbender L; Kanzy EJ; Piepenbrock M; Seiler FR Immunobiology; 1986 Apr; 171(3):252-62. PubMed ID: 3011651 [TBL] [Abstract][Full Text] [Related]
34. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D. Hong K; Kinoshita T; Pramoonjago P; Kim YU; Seya T; Inoue K J Immunol; 1991 Mar; 146(6):1868-73. PubMed ID: 2005382 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. Sahu A; Kay BK; Lambris JD J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942 [TBL] [Abstract][Full Text] [Related]
36. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296 [TBL] [Abstract][Full Text] [Related]
37. Activation of the alternative complement pathway. Fearon DT CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484 [No Abstract] [Full Text] [Related]
38. Role of C3 in the control of monocyte C2 production. Hamilton AO; Morrison L; Kilpatrick WS; Lappin D; Bensa JC; Riches DW; Whaley K Immunology; 1984 Jan; 51(1):169-76. PubMed ID: 6690395 [TBL] [Abstract][Full Text] [Related]
39. C3 activation by a new factor B-dependent enzyme detected in culture supernatant from guinea-pig peritoneal macrophages. Beuscher HU; Brade V Immunology; 1986 Aug; 58(4):545-51. PubMed ID: 3089917 [TBL] [Abstract][Full Text] [Related]
40. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Gadd KJ; Reid KB Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]